Modern Drug Discovery

Meeting the challenge of increased productivity in early drug discovery requires increased knowledge to make better decisions on compounds. The massive amount of data on targets generated from genomics, proteomics, and high-throughput screening campaigns demands a context in which these stores of information can be combined into valuable knowledge. The living cell, with its amazing integrative abilities of environmental detection, molecular signal ampli-fication and processing, and repertoire of genome-level responses to perturbation, is providing the knowledge-building framework from which a new vision of drug discovery is being con-structed.

For full article click here.

Modern Drug Discovery is a publication of the American Chemical Society, and is available without cost to qualified subscribers in the U.S. and Europe. Online subscription information can be found at www.moderndrugdiscovery.org

To make any comments on this article, or to ask a question of the author, please contact the publisher. If you would like to submit an article please subscribe to our PL Intelligence service.

The opinions expressed in the articles published in this section do not necessarily reflect those of Pharmalicensing or UTEK Corporation. No actions including proposals to or agreements with other companies should be taken by any reader without obtaining specific business or legal advice. Neither the publisher nor the authors accept any liability for any actions or activities undertaken by any reader or other third party as a consequence of these articles or for any errors or omissions therein.